{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:06:09Z","timestamp":1790622369631,"version":"4.1.0"},"reference-count":193,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["094849\/Z\/10\/Z"],"award-info":[{"award-number":["094849\/Z\/10\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012176","name":"Maudsley Charity","doi-asserted-by":"publisher","award":["666"],"award-info":[{"award-number":["666"]}],"id":[{"id":"10.13039\/100012176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009360","name":"King\u2019s College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009360","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_U120097115"],"award-info":[{"award-number":["MC_U120097115"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009362","name":"South London and Maudsley NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience &amp; Biobehavioral Reviews"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.neubiorev.2021.11.032","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T11:09:54Z","timestamp":1637752194000},"page":"324-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"special_numbering":"C","title":["New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5154-9907","authenticated-orcid":false,"given":"Maria C.","family":"Lobo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7005-902X","authenticated-orcid":false,"given":"Thomas S.","family":"Whitehurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver D.","family":"Howes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.neubiorev.2021.11.032_bib0005","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1517\/14656560802532707","article-title":"Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders","volume":"9","author":"Abbas","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"issue":"Supplement_1","key":"10.1016\/j.neubiorev.2021.11.032_bib0010","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1093\/schbul\/sbaa029.602","article-title":"T42. High adherence to current antipsychotic and adjunctive Pimavanserin in the enhance study, a phase 3 trial to evaluate the treatment of schizophrenia in patients with an inadequate response to antipsychotic treatment","volume":"46","author":"Abbs","year":"2020","journal-title":"Schizophr. Bull."},{"issue":"11","key":"10.1016\/j.neubiorev.2021.11.032_bib0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4088\/JCP.13078tx2c","article-title":"Schizophrenia: overview and dopamine dysfunction","volume":"75","author":"Abi-Dargham","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0020","series-title":"Nuplazid (pimavanserin) [package insert]","author":"Acadia Pharmaceuticals Inc","year":"2016"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0025","series-title":"ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia","author":"Acadia Pharmaceuticals Inc","year":"2019"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0030","series-title":"Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)","author":"Acadia Pharmaceuticals Inc","year":"2020"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0035","series-title":"NCT02970292- Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)","author":"Acadia Pharmaceuticals Inc","year":"2020"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0040","series-title":"NCT02970305- Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)","author":"Acadia Pharmaceuticals Inc","year":"2020"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0045","series-title":"ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia","author":"Acadia Pharmaceuticals INC","year":"2019"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0050","series-title":"NCT03121586- Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia","author":"Acadia Pharmaceuticals INC","year":"2020"},{"issue":"Suppl. 1","key":"10.1016\/j.neubiorev.2021.11.032_bib0055","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1093\/schbul\/sbx021.037","article-title":"18. Evenamide, a putative antipsychotic, targets abnormal electrical activity and glutamatergic abnormalities to improve psychotic symptoms in patients with schizophrenia: results from a phase II, placebo-controlled trial","volume":"43","author":"Anand","year":"2017","journal-title":"Schizophr. Bull."},{"issue":"Suppl. 1","key":"10.1016\/j.neubiorev.2021.11.032_bib0060","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1093\/schbul\/sby016.324","article-title":"T48. Antipsychotic efficacy of Evenamide (NW-3509) is due to modulation of glutamatergic dysregulation","volume":"44","author":"Anand","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0065","series-title":"Agonist","author":"Atack","year":"2010"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0070","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3389\/fphar.2020.00591","article-title":"Identification of a serotonin 2A receptor subtype of schizophrenia spectrum disorders with pimavanserin: the sub-sero proof-of-concept trial protocol","volume":"11","author":"Baltzersen","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0075","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2147\/NDT.S301225","article-title":"Safety and tolerability of cariprazine in patients with schizophrenia: a pooled analysis of eight phase II\/III studies","volume":"17","author":"Barab\u00e1ssy","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881119889296","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology","volume":"34","author":"Barnes","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0085","first-page":"171","article-title":"Evenamide\u2013a new hope for treatment resistant schizophrenia","volume":"1","author":"Bhatia","year":"2019","journal-title":"Delhi Psychiatry J."},{"issue":"S1","key":"10.1016\/j.neubiorev.2021.11.032_bib0090","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1016\/j.eurpsy.2017.02.428","article-title":"Efficacy of F17464, a new preferential D3 antagonist in a placebo-controlled phase 2 study of patients with an acute exacerbation of schizophrenia","volume":"41","author":"Bitter","year":"2017","journal-title":"Eur. Psychiatry"},{"issue":"11","key":"10.1016\/j.neubiorev.2021.11.032_bib0095","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41386-019-0355-2","article-title":"Randomized, double-blind, placebo-controlled study of F17464, a preferential D 3 antagonist, in the treatment of acute exacerbation of schizophrenia","volume":"44","author":"Bitter","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0100","first-page":"1","article-title":"Lumateperone: first approval","author":"Blair","year":"2020","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0105","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/schbul\/sbj013","article-title":"The structure of negative symptoms within schizophrenia: implications for assessment","volume":"32","author":"Blanchard","year":"2006","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0110","doi-asserted-by":"crossref","first-page":"e2569","DOI":"10.1002\/hup.2569","article-title":"A phase I, randomized, proof\u2010of\u2010clinical\u2010mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers","volume":"32","author":"Boland","year":"2017","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"issue":"8","key":"10.1016\/j.neubiorev.2021.11.032_bib0115","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40120-017-0085-5","article-title":"A phase Ic study evaluating the safety, tolerability, pharmacokinetics, and cognitive outcomes of BI 409306 in patients with mild-to-moderate schizophrenia","volume":"7","author":"Brown","year":"2018","journal-title":"Neurol. Ther."},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0125","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/schbul\/sby049","article-title":"Evaluation of the efficacy, safety, and tolerability of BI 409306, a novel phosphodiesterase 9 inhibitor, in cognitive impairment in schizophrenia: a randomized, double-blind, placebo-controlled, phase II trial","volume":"45","author":"Brown","year":"2019","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.neubiorev.2021.11.032_bib0130","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2019.07.008","article-title":"Heterogeneity of striatal dopamine function in schizophrenia: meta-analysis of variance","volume":"87","author":"Brugger","year":"2020","journal-title":"Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.neubiorev.2021.11.032_bib0135","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.euroneuro.2014.03.007","article-title":"A phase II\/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia\u2013results from the CandleLyte study","volume":"24","author":"Bugarski-Kirola","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.neubiorev.2021.11.032_bib0140","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S2215-0366(16)30344-3","volume":"3","author":"Bugarski-Kirola","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.neubiorev.2021.11.032_bib0145","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1093\/schbul\/sbaa029.601","article-title":"T41. Safety profile of adjunctive pimavanserin in the enhance study, a phase 3 trial for the potential treatment of schizophrenia in patients with an inadequate response to antipsychotic treatment","volume":"46","author":"Bugarski-Kirola","year":"2020","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0150","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0155","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/(SICI)1098-2299(199702)40:2<158::AID-DDR6>3.0.CO;2-K","article-title":"Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer\u2019s disease","volume":"40","author":"Bymaster","year":"1997","journal-title":"Drug Dev. Res."},{"issue":"2\u20133","key":"10.1016\/j.neubiorev.2021.11.032_bib0160","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0014-2999(98)00487-7","article-title":"Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R, 6R) 6-(3-propylthio-1, 2, 5-thiadiazol-4-yl)-1-azabicyclo [3.2. 1] octane","volume":"356","author":"Bymaster","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0165","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.schres.2017.09.010","article-title":"Response to concerns over Cantillon et al. dopamine serotonin stabilizer RP5063 clinical trial\u2019s design, analyses and findings (SCHRES-D-17-00455) by Ahmed S Aboraya, MD, DrPh","volume":"195","author":"Cantillon","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0170","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.schres.2017.01.043","article-title":"Dopamine serotonin stabilizer RP5063: a randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder","volume":"189","author":"Cantillon","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0175","series-title":"Future Research Needs for First- and Second- Generation Antipsychotics for Children and Young Adults","article-title":"Appendix A, tables of FDA-approved indications for first- and second- generation antipsychotics","author":"Christian","year":"2012"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0180","series-title":"Antagonist [Homepage of Springer, Berlin, Heidelberg], [Online]","author":"Christopoulos","year":"2010"},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/17425255.2013.759211","article-title":"Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability","volume":"9","author":"Citrome","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0190","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/JCP.0000000000000665","article-title":"Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm","volume":"37","author":"Citrome","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.neubiorev.2021.11.032_bib0195","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/YIC.0000000000000123","article-title":"The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study","volume":"31","author":"Citrome","year":"2016","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0200","series-title":"Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults with Early-Episode Schizophrenia","author":"Clinicaltrials.Gov","year":"2016"},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0205","doi-asserted-by":"crossref","first-page":"36","DOI":"10.24869\/psyd.2020.36","article-title":"Efficacy and safety of cariprazine in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials","volume":"32","author":"Cooper","year":"2020","journal-title":"Psychiatr. Danub."},{"issue":"6","key":"10.1016\/j.neubiorev.2021.11.032_bib0210","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/YIC.0000000000000189","article-title":"Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials","volume":"32","author":"Corponi","year":"2017","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.neubiorev.2021.11.032_bib0215","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.euroneuro.2019.06.008","article-title":"Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone","volume":"29","author":"Corponi","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"9","key":"10.1016\/j.neubiorev.2021.11.032_bib0220","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/appi.ajp.2015.14101275","article-title":"Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial","volume":"172","author":"Correll","year":"2015","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.neubiorev.2021.11.032_bib0225","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.schres.2016.04.012","article-title":"Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies","volume":"174","author":"Correll","year":"2016","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.neubiorev.2021.11.032_bib0230","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jamapsychiatry.2019.4379","article-title":"Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial","volume":"77","author":"Correll","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0235","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.schres.2020.12.006","article-title":"Safety and tolerability of lumateperone 42 mg: an open-label antipsychotic switch study in outpatients with stable schizophrenia","volume":"228","author":"Correll","year":"2021","journal-title":"Schizophr. Res."},{"issue":"S1","key":"10.1016\/j.neubiorev.2021.11.032_bib0240","doi-asserted-by":"crossref","first-page":"s807","DOI":"10.1016\/j.eurpsy.2017.01.1562","article-title":"F17464 a new antipsychotic with preferential D3 antagonist, 5-HT1A partial agonist properties. Neurochemical studies","volume":"41","author":"Cosi","year":"2017","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173635","article-title":"Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist","volume":"890","author":"Cosi","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"9916","key":"10.1016\/j.neubiorev.2021.11.032_bib0250","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.neubiorev.2021.11.032_bib0255","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1176\/appi.ajp.2017.17010122","article-title":"Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia","volume":"174","author":"Davidson","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.neubiorev.2021.11.032_bib0260","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14737175.2016.1174577","article-title":"ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes","volume":"16","author":"Davis","year":"2016","journal-title":"Expert Rev Neurother."},{"issue":"suppl_1","key":"10.1016\/j.neubiorev.2021.11.032_bib0265","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1093\/schbul\/sby017.577","article-title":"F46. Lumateperone (ITI-007): favorable safety profile in an open label safety switching study from standard-of-care antipsychotic therapy in patients with schizophrenia","volume":"44","author":"Davis","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.119.260281","article-title":"SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action","volume":"371","author":"Dedic","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"11","key":"10.1016\/j.neubiorev.2021.11.032_bib0275","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1017\/S0033291717000435","article-title":"Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors","volume":"47","author":"Demjaha","year":"2017","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0280","first-page":"1","article-title":"Medication-induced akathisia with newly approved antipsychotics in patients with a severe mental illness: a systematic review and meta-analysis","author":"Demyttenaere","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0285","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fnmol.2014.00060","article-title":"PDE9A is expressed in the inner retina and contributes to the normal shape of the photopic ERG waveform","volume":"7","author":"Dhingra","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0290","first-page":"231","article-title":"Role of PDE9 in cognition","author":"Dorner-Ciossek","year":"2017","journal-title":"Phosphodiesterases: CNS Funct. Diseases"},{"issue":"2\u20133","key":"10.1016\/j.neubiorev.2021.11.032_bib0295","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial","volume":"152","author":"Durgam","year":"2014","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.neubiorev.2021.11.032_bib0300","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.4088\/JCP.15m09997","article-title":"Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial","volume":"76","author":"Durgam","year":"2015","journal-title":"J. Clin. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.neubiorev.2021.11.032_bib0305","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.schres.2016.06.030","article-title":"Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"176","author":"Durgam","year":"2016","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0310","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/YIC.0000000000000110","article-title":"Cariprazine in the treatment of schizophrenia: a proof-of-concept trial","volume":"31","author":"Durgam","year":"2016","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.neubiorev.2021.11.032_bib0315","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13037","article-title":"Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: a pooled post hoc analysis","volume":"71","author":"Durgam","year":"2017","journal-title":"Int. J. Clin. Pract."},{"issue":"6","key":"10.1016\/j.neubiorev.2021.11.032_bib0320","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/YIC.0000000000000187","article-title":"Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II\/III randomized, double-blind, placebo-controlled studies","volume":"32","author":"Earley","year":"2017","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.neubiorev.2021.11.032_bib0325","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/13543784.2011.601738","article-title":"Serotonin 2A receptor antagonists for treatment of schizophrenia","volume":"20","author":"Ebdrup","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0330","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1017\/S1092852920002436","article-title":"Cardiometabolic safety of lumateperone (ITI\u2212 007): post hoc analyses of short-term randomized trials and an open-label long-term study in schizophrenia","volume":"26","author":"Edwards","year":"2021","journal-title":"CNS Spectr."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0335","series-title":"Summary of Product Characteristics: Cariprazine","author":"EUROPEAN MEDICINES AGENCY","year":"2021"},{"issue":"23","key":"10.1016\/j.neubiorev.2021.11.032_bib0340","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1021\/jm990607u","article-title":"Therapeutic opportunities for muscarinic receptors in the central nervous system","volume":"43","author":"Felder","year":"2000","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0345","first-page":"130","article-title":"New schizophrenia treatments address unmet clinical needs","volume":"42","author":"Fellner","year":"2017","journal-title":"Pharm. Ther."},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0350","first-page":"11","article-title":"Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"20","author":"Fleischhacker","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2021.11.032_bib0355","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2215-0366(20)30513-7","article-title":"Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study","volume":"8","author":"Fleischhacker","year":"2021","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"10.1016\/j.neubiorev.2021.11.032_bib0360","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/ijnp\/pyy002","article-title":"A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as maintenance treatment in adults with schizophrenia","volume":"21","author":"Forbes","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.neubiorev.2021.11.032_bib0365","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40263-017-0442-z","article-title":"Cariprazine: a review in schizophrenia","volume":"31","author":"Garnock-Jones","year":"2017","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.neubiorev.2021.11.032_bib0370","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.3390\/ijms22094467","article-title":"Beyond dopamine receptor antagonism: new targets for schizophrenia treatment and prevention","volume":"22","author":"Gomes","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0375","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"10","key":"10.1016\/j.neubiorev.2021.11.032_bib0380","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1007\/s11064-014-1293-3","article-title":"On the discovery and development of pimavanserin: a novel drug candidate for Parkinson\u2019s psychosis","volume":"39","author":"Hacksell","year":"2014","journal-title":"Neurochem. Res."},{"issue":"suppl_1","key":"10.1016\/j.neubiorev.2021.11.032_bib0385","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1093\/schbul\/sby015.234","article-title":"O7. 5. Long-term safety and tolerability of brexpiprazole in patients with schizophrenia","volume":"44","author":"Hakala","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.neubiorev.2021.11.032_bib0390","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2021.11.032_bib0395","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/schbul\/sbx101","article-title":"Transformed PANSS factors intended to reduce pseudospecificity among symptom domains and enhance understanding of symptom change in antipsychotic-treated patients with schizophrenia","volume":"44","author":"Hopkins","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.neubiorev.2021.11.032_bib0400","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4088\/JCP.v68n0302","article-title":"Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder","volume":"68","author":"Howes","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"9929","key":"10.1016\/j.neubiorev.2021.11.032_bib0405","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(13)62036-X","article-title":"Schizophrenia: an integrated sociodevelopmental-cognitive model","volume":"383","author":"Howes","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.neubiorev.2021.11.032_bib0410","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.jcp.0000162798.87249.4d","article-title":"Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment","volume":"25","author":"Howes","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0415","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/wps.20822","article-title":"The clinical significance of duration of untreated psychosis: an umbrella review and random\u2010effects meta\u2010analysis","volume":"20","author":"Howes","year":"2021","journal-title":"World Psychiatry"},{"issue":"10202","key":"10.1016\/j.neubiorev.2021.11.032_bib0420","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.neubiorev.2021.11.032_bib0425","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/pcn.12682","article-title":"Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: a 6\u2010week, randomized, double\u2010blind, placebo\u2010controlled study","volume":"72","author":"Ishigooka","year":"2018","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0430","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/JCP.0000000000000979","article-title":"Effect of brexpiprazole on prolactin: an analysis of short-and long-term studies in schizophrenia","volume":"39","author":"Ivkovic","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0435","series-title":"Partial Agonist","author":"Jackson","year":"2010"},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0440","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.biopsych.2018.07.003","article-title":"The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: a positron emission tomography study","volume":"85","author":"Jauhar","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2021.07.027","article-title":"Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: a long and winding road","author":"Kadriu","year":"2021","journal-title":"Drug Discov. Today"},{"issue":"1\u20133","key":"10.1016\/j.neubiorev.2021.11.032_bib0455","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2015.01.038","article-title":"A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia","volume":"164","author":"Kane","year":"2015","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.neubiorev.2021.11.032_bib0460","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial","volume":"35","author":"Kane","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.neubiorev.2021.11.032_bib0465","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.schres.2016.04.013","article-title":"Overview of short-and long-term tolerability and safety of brexpiprazole in patients with schizophrenia","volume":"174","author":"Kane","year":"2016","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0470","doi-asserted-by":"crossref","first-page":"0","DOI":"10.4088\/JCP.18com12123","article-title":"Clinical guidance on the identification and management of treatment-resistant schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0475","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1017\/S1092852920001005","article-title":"185 the safety and tolerability of lumateperone 42 mg for the treatment of schizophrenia: a pooled analysis of 3 randomized placebo-controlled trials","volume":"25","author":"Kane","year":"2020","journal-title":"CNS Spectr."},{"issue":"3","key":"10.1016\/j.neubiorev.2021.11.032_bib0480","doi-asserted-by":"crossref","first-page":"0","DOI":"10.4088\/JCP.17m11753","article-title":"Cognitive effects of MIN-101 in patients with schizophrenia and negative symptoms: results from a randomized controlled trial","volume":"79","author":"Keefe","year":"2018","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0485","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0490","first-page":"1","article-title":"Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis","author":"Kishi","year":"2020","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0495","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3\/D2 dopamine receptor antagonist\u2013partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1\u20132","key":"10.1016\/j.neubiorev.2021.11.032_bib0500","first-page":"16","article-title":"Pimavanserin: a novel drug approved to treat Parkinson\u2019s disease psychosis","volume":"15","author":"Kitten","year":"2018","journal-title":"Innov. Clin. Neurosci."},{"issue":"16","key":"10.1016\/j.neubiorev.2021.11.032_bib0505","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","article-title":"A non\u2013D2-receptor-binding drug for the treatment of schizophrenia","volume":"382","author":"Koblan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0510","first-page":"1","article-title":"Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine","author":"Kokkinou","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0515","first-page":"1","article-title":"Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine","author":"Kokkinou","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"7","key":"10.1016\/j.neubiorev.2021.11.032_bib0520","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00406-018-0869-3","article-title":"Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis","volume":"268","author":"Krause","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"S1","key":"10.1016\/j.neubiorev.2021.11.032_bib0525","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S109285291900124X","article-title":"Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities","volume":"24","author":"Krogmann","year":"2019","journal-title":"CNS Spectr."},{"issue":"15","key":"10.1016\/j.neubiorev.2021.11.032_bib0530","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1017\/S0033291716002014","article-title":"Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses","volume":"46","author":"Lally","year":"2016","journal-title":"Psychol. Med."},{"issue":"11","key":"10.1016\/j.neubiorev.2021.11.032_bib0535","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s40263-016-0382-z","article-title":"Tolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder and major depressive disorder: a systematic review with meta-analysis of randomized controlled trials","volume":"30","author":"Lao","year":"2016","journal-title":"CNS Drugs"},{"issue":"9896","key":"10.1016\/j.neubiorev.2021.11.032_bib0540","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"9896","key":"10.1016\/j.neubiorev.2021.11.032_bib0545","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.neubiorev.2021.11.032_bib0550","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopsych.2015.08.026","article-title":"ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial","volume":"79","author":"Lieberman","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0555","series-title":"Compositions and Methods for Treating Schizophrenia","author":"Luthringer","year":"2016"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0560","series-title":"Methods of Use of Cyclic Amide Derivatives to Treat Schizophrenia","author":"Luthringer","year":"2013"},{"issue":"3","key":"10.1016\/j.neubiorev.2021.11.032_bib0565","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0570","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","author":"Marder","year":"1997","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.neubiorev.2021.11.032_bib0575","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1017\/neu.2016.57","article-title":"Brexpiprazole in patients with schizophrenia: overview of short-and long-term phase 3 controlled studies","volume":"29","author":"Marder","year":"2017","journal-title":"Acta Neuropsychiatr."},{"issue":"3","key":"10.1016\/j.neubiorev.2021.11.032_bib0580","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1017\/neu.2020.8","article-title":"Post hoc analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia","volume":"32","author":"Marder","year":"2020","journal-title":"Acta Neuropsychiatr."},{"issue":"10","key":"10.1016\/j.neubiorev.2021.11.032_bib0585","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40265-016-0597-9","article-title":"Pimavanserin: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.neubiorev.2021.11.032_bib0590","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/appi.ajp.2018.18030280","article-title":"Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia","volume":"176","author":"Martin","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.neubiorev.2021.11.032_bib0595","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s40262-018-0664-3","article-title":"Clinical pharmacokinetics of atypical antipsychotics: an update","volume":"57","author":"Mauri","year":"2018","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.neubiorev.2021.11.032_bib0600","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/schbul\/sbx180","article-title":"Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis","volume":"44","author":"Mccutcheon","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0605","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wps.20693","article-title":"Dopamine and glutamate in schizophrenia: biology, symptoms and treatment","volume":"19","author":"Mccutcheon","year":"2020","journal-title":"World Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0610","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia\u2014An overview","volume":"77","author":"Mccutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0615","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-3-642-25758-2_9","article-title":"Muscarinic mechanisms in psychotic disorders","author":"Mckinzie","year":"2012","journal-title":"Novel Antischizophrenia Treat."},{"issue":"8","key":"10.1016\/j.neubiorev.2021.11.032_bib0620","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/0269881120936485","article-title":"Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms: post-hoc analysis of short-and long-term studies","volume":"34","author":"Meade","year":"2020","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.neubiorev.2021.11.032_bib0625","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin 2A receptor inverse agonist, for the treatment of Parkinson\u2019s disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0630","first-page":"33","article-title":"Lumateperone for schizophrenia","volume":"19","author":"Meyer","year":"2020","journal-title":"Curr. Psychiatr."},{"issue":"Suppl. 1","key":"10.1016\/j.neubiorev.2021.11.032_bib0635","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1093\/schbul\/sbaa030.520","article-title":"M208. Measures of cognition and social functioning in schizophrenia patients receiving SEP-363856","volume":"46","author":"Milanovic","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0640","author":"Minerva Neurosciences Inc","year":"2020"},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0645","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2003.tb00247.x","article-title":"Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists","volume":"9","author":"Mirza","year":"2003","journal-title":"CNS Drug Rev."},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0650","doi-asserted-by":"crossref","first-page":"0","DOI":"10.4088\/JCP.18m12246","article-title":"Prevalence of and risk factors for extrapyramidal side effects of antipsychotics: results from the national FACE-SZ cohort","volume":"80","author":"Misdrahi","year":"2019","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2021.11.032_bib0655","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41386-019-0577-3","article-title":"Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis","volume":"45","author":"Mizuno","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.neubiorev.2021.11.032_bib0660","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/bcp.13060","article-title":"First\u2010in\u2010human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males","volume":"82","author":"Moschetti","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.neubiorev.2021.11.032_bib0665","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40261-018-0660-2","article-title":"Multiple rising doses of oral BI 425809, a GlyT1 inhibitor, in young and elderly healthy volunteers: a randomised, double-blind, phase I study investigating safety and pharmacokinetics","volume":"38","author":"Moschetti","year":"2018","journal-title":"Clin. Drug Investig."},{"issue":"9859","key":"10.1016\/j.neubiorev.2021.11.032_bib0670","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","article-title":"Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.neubiorev.2021.11.032_bib0675","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1192\/bjp.bp.116.182683","article-title":"Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?","volume":"209","author":"Murray","year":"2016","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0680","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12888-017-1459-z","article-title":"The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis","volume":"17","author":"Nasrallah","year":"2017","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0685","series-title":"Treatment Summary: Psychoses and Related Disorders","author":"NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE, (UK)","year":"2021"},{"issue":"10074","key":"10.1016\/j.neubiorev.2021.11.032_bib0690","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial","volume":"389","author":"N\u00e9meth","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.neubiorev.2021.11.032_bib0695","first-page":"116","article-title":"Polypharmacological Drugs in Treatment of Schizophrenia","volume":"2","author":"Nerkar","year":"2020","journal-title":"Curr. Trends Pharm. Pharm. Chem."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0700","series-title":"NCT03055338: an Active-Controlled Early Phase Study of MK-8189 in Adults with Schizophrenia","author":"NIH U.S. NATIONAL LIBRARY OF MEDICINE","year":"2018"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0705","series-title":"NCT02717195: Effect of Lu AF35700 in Patients with Treatment-resistant Schizophrenia (DayBreak)","author":"NIH U.S. NATIONAL LIBRARY OF MEDICINE","year":"2019"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0710","series-title":"NCT02333487: Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700","author":"NIH U.S. NATIONAL LIBRARY OF MEDICINE","year":"2020"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0715","series-title":"NCT02892422: Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients with Schizophrenia (Debut)","author":"NIH U.S. NATIONAL LIBRARY OF MEDICINE","year":"2020"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0720","series-title":"NCT03230864: Efficacy of Lu AF35700 in Patients with Early-in-Disease or Late-in-Disease Treatment-Resistant Schizophrenia (Anew)","author":"NIH U.S. NATIONAL LIBRARY OF MEDICINE","year":"2020"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0725","series-title":"NCT 03565068: a Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants with Schizophrenia and in Healthy Participants","author":"NIH U.S. NATIONAL LIBRARY OF MEDICINE","year":"2021"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0730","series-title":"NCT03319953: a Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-on to Antipsychotics in Participants with Stable Schizophrenia","author":"NIH U.S. NATIONAL LIBRARY OF MEDICINE","year":"2021"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0735","series-title":"NCT03669640: a Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants with Schizophrenia or Schizoaffective Disorder and Negative Symptoms","author":"NIH U.S. NATIONAL LIBRARY OF MEDICINE","year":"2021"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0740","series-title":"NCT03745820: a Study to Evaluate the Safety and Efficacy of BIIB104 in Participants with Cognitive Impairment Associated With Schizophrenia (CIAS) (TALLY)","author":"NIH U.S. NATIONAL LIBRARY OF MEDICINE","year":"2021"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0745","series-title":"NCT04512066: a Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients with an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder","author":"NIH U.S. NATIONAL LIBRARY OF MEDICINE","year":"2021"},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0750","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1461145707007869","article-title":"PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain","volume":"11","author":"Nordstrom","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0755","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1192\/bjp.2019.268","article-title":"Cardiac structure and function in schizophrenia: cardiac magnetic resonance imaging study","volume":"217","author":"Osimo","year":"2020","journal-title":"Br. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.neubiorev.2021.11.032_bib0760","first-page":"638","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"Patel","year":"2014","journal-title":"Pharm. Ther."},{"issue":"6","key":"10.1016\/j.neubiorev.2021.11.032_bib0765","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1192\/bjp.bp.117.200907","article-title":"Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis","volume":"211","author":"Pillinger","year":"2017","journal-title":"Br. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.neubiorev.2021.11.032_bib0770","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41380-018-0058-9","article-title":"Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models","volume":"24","author":"Pillinger","year":"2019","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0775","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0780","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0785","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-019-0090-z","article-title":"The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research","volume":"6","author":"Potkin","year":"2020","journal-title":"NPJ Schizophr."},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0790","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12769","article-title":"Efficacy and safety of a combination of olanzapine and samidorphan in adult patients with an acute exacerbation of schizophrenia: outcomes from the randomized, phase 3 ENLIGHTEN-1 study","volume":"81","author":"Potkin","year":"2020","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2021.11.032_bib0795","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/YIC.0000000000000351","article-title":"The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study","volume":"36","author":"Rancans","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"15","key":"10.1016\/j.neubiorev.2021.11.032_bib0800","doi-asserted-by":"crossref","first-page":"11527","DOI":"10.1021\/acs.jmedchem.1c00820","article-title":"Discovery of TAK-041: a potent and selective GPR139 agonist explored for the treatment of negative symptoms associated with schizophrenia","volume":"64","author":"Reichard","year":"2021","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.neubiorev.2021.11.032_bib0805","doi-asserted-by":"crossref","first-page":"8485","DOI":"10.1073\/pnas.1103029108","article-title":"TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity","volume":"108","author":"Revel","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.neubiorev.2021.11.032_bib0810","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3928\/00485713-20190213-01","article-title":"Cariprazine: pharmacology and use in the clinical management of psychiatric disorders","volume":"49","author":"Reyad","year":"2019","journal-title":"Psychiatr. Ann."},{"issue":"3","key":"10.1016\/j.neubiorev.2021.11.032_bib0815","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","article-title":"Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder","volume":"56","author":"Robinson","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0820","unstructured":"Roth, B., Lopez, E. PDSP Ki database. Available: https:\/\/pdsp.unc.edu\/databases\/kidb.php [05 May, 2021]."},{"issue":"21","key":"10.1016\/j.neubiorev.2021.11.032_bib0825","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2165\/00003495-200464210-00005","article-title":"Trospium chloride in the management of overactive bladder","volume":"64","author":"Rovner","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0830","article-title":"Additional results from a 12-month open-label safety study of lumateperone (ITI-007) in patients with stable symptoms of schizophrenia [abstract no. W203 plus poster]","author":"Satlin","year":"2019","journal-title":"58th Annual Meeting of the American College of Neuropsychopharmacology 2019"},{"issue":"Supplement_1","key":"10.1016\/j.neubiorev.2021.11.032_bib0835","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1093\/schbul\/sbaa030.517","article-title":"M205. Long-term safety of lumateperone (ITI-007): metabolic effects in a 1-year study","volume":"46","author":"Satlin","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0840","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.neubiorev.2014.06.005","article-title":"Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies","volume":"45","author":"Selvaraj","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"8","key":"10.1016\/j.neubiorev.2021.11.032_bib0845","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0850","series-title":"What is GRADE","author":"Siemieniuk","year":"2019"},{"issue":"9","key":"10.1016\/j.neubiorev.2021.11.032_bib0855","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1358\/dof.2019.44.9.2921069","article-title":"Evenamide hydrochloride. Voltage-gated sodium channel blocker, treatment of schizophrenia","volume":"44","author":"Singh","year":"2019","journal-title":"Drugs Future"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0860","series-title":"Affinity","author":"Slifstein","year":"2010"},{"issue":"4","key":"10.1016\/j.neubiorev.2021.11.032_bib0865","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamapsychiatry.2014.2414","article-title":"Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study","volume":"72","author":"Slifstein","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0870","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00213-019-05387-w","article-title":"Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [11 C]-(\u202f)-PHNO","volume":"237","author":"Slifstein","year":"2020","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1016\/j.neubiorev.2021.11.032_bib0875","doi-asserted-by":"crossref","first-page":"67","DOI":"10.17116\/jnevro202012012167","article-title":"Cariprazine in schizophrenia with predominantly negative symptoms: early effects of therapy (observational study)","volume":"120","author":"Smulevich","year":"2020","journal-title":"Zhurnal Nevrologii I Psikhiatrii Imeni Ss Korsakova"},{"issue":"3","key":"10.1016\/j.neubiorev.2021.11.032_bib0880","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00213-014-3704-1","article-title":"Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission","volume":"232","author":"Snyder","year":"2015","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0885","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/ejn.13390","article-title":"The dopamine D3 receptor, a quarter century later","volume":"45","author":"Sokoloff","year":"2017","journal-title":"Eur. J. Neurosci."},{"issue":"5","key":"10.1016\/j.neubiorev.2021.11.032_bib0890","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1017\/S1092852917000608","article-title":"Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes","volume":"22","author":"Stahl","year":"2017","journal-title":"CNS Spectr."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0895","series-title":"Inverse Agonists","author":"Stewart","year":"2010"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0900","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.00061","article-title":"Cariprazine safety in adolescents and the elderly: analyses of clinical study data","volume":"11","author":"Szatm\u00e1ri","year":"2020","journal-title":"Front. Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2021.11.032_bib0905","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ejphar.2011.07.020","article-title":"In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors","volume":"668","author":"Tadori","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0910","series-title":"Schizophrenia and Related Psychoses. The Maudsley Prescribing Guidelines in Psychiatry","first-page":"3","author":"Taylor","year":"2018"},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0915","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/NDT.S34433","article-title":"Profile of blonanserin for the treatment of schizophrenia","volume":"9","author":"Tenjin","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.neubiorev.2021.11.032_bib0920","series-title":"Calypta Prescribing Information","author":"U.S. FOOD AND DRUG ADMINISTRATION","year":"2019"},{"issue":"6809","key":"10.1016\/j.neubiorev.2021.11.032_bib0925","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/35041572","article-title":"Distinct functions of the two isoforms of dopamine D2 receptors","volume":"408","author":"Usiello","year":"2000","journal-title":"Nature"},{"issue":"suppl_1","key":"10.1016\/j.neubiorev.2021.11.032_bib0930","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1093\/schbul\/sby018.831","article-title":"S44. Lumateperone (ITI-007) for the treatment of schizophrenia: placebo-controlled clinical trials and an open-label safety switching study","volume":"44","author":"Vanover","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.neubiorev.2021.11.032_bib0935","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41386-018-0251-1","article-title":"Dopamine D 2 receptor occupancy of lumateperone (ITI-007): a positron emission tomography study in patients with schizophrenia","volume":"44","author":"Vanover","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neubiorev.2021.11.032_bib0940","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/jpet.105.097006","article-title":"Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N\u2032-(4-(2-methylpropyloxy) phenylmethyl) carbamide (2R, 3R)-dihydroxybutanedioate (2: 1)(ACP-103), a novel 5-hydroxytryptamine2A receptor inverse agonist","volume":"317","author":"Vanover","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"10053","key":"10.1016\/j.neubiorev.2021.11.032_bib0945","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Vos","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.neubiorev.2021.11.032_bib0950","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/sj.bjp.0702201","article-title":"Functional effects of the muscarinic receptor agonist, xanomeline, at 5\u2010HT1 and 5\u2010HT2 receptors","volume":"125","author":"Watson","year":"1998","journal-title":"Br. J. Pharmacol."},{"issue":"10132","key":"10.1016\/j.neubiorev.2021.11.032_bib0955","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(18)31002-X","article-title":"Pimavanserin evaluated by the FDA","volume":"391","author":"Webster","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.neubiorev.2021.11.032_bib0960","article-title":"The presynaptic D2 partial agonist lumateperone acts as a postsynaptic D2 antagonist","volume":"4","author":"Zhang","year":"2018","journal-title":"Matters"},{"issue":"1","key":"10.1016\/j.neubiorev.2021.11.032_bib0965","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/JCP.0000000000000834","article-title":"Efficacy and acceptability of cariprazine in acute exacerbation of schizophrenia: meta-analysis of randomized placebo-controlled trials","volume":"38","author":"Zhao","year":"2018","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["Neuroscience &amp; Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763421005261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763421005261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T19:34:16Z","timestamp":1720985656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763421005261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":193,"alternative-id":["S0149763421005261"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2021.11.032","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2021.11.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2021 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}